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Abstract
The objective of these studies was to develop Cremophor-free lipid-based paclitaxel (PX)
nanoparticle formulations prepared from warm microemulsion precursors. To identify and optimize
new nanoparticles, experimental design was performed combining Taguchi array and sequential
simplex optimization. The combination of Taguchi array and sequential simplex optimization
efficiently directed the design of paclitaxel nanoparticles. Two optimized paclitaxel nanoparticles
(NPs) were obtained: G78 NPs composed of glyceryl tridodecanoate (GT) and polyoxyethylene 20-
stearyl ether (Brij 78), and BTM NPs composed of Miglyol 812, Brij 78 and D-alpha-tocopheryl
polyethylene glycol 1000 succinate (TPGS). Both nanoparticles successfully entrapped paclitaxel at
a final concentration of 150 μg/ml (over 6% drug loading) with particle sizes less than 200 nm and
over 85% of entrapment efficiency. These novel paclitaxel nanoparticles were stable at 4°C over
three months and in PBS at 37°C over 102 hours as measured by physical stability. Release of
paclitaxel was slow and sustained without initial burst release. Cytotoxicity studies in MDA-MB-231
cancer cells showed that both nanoparticles have similar anticancer activities compared to Taxol®.
Interestingly, PX BTM nanocapsules could be lyophilized without cryoprotectants. The lyophilized
powder comprised only of PX BTM NPs in water could be rapidly rehydrated with complete retention
of original physicochemical properties, in-vitro release properties, and cytotoxicity profile.
Sequential Simplex Optimization has been utilized to identify promising new lipid-based paclitaxel
nanoparticles having useful attributes.
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Paclitaxel is one of the most effective anticancer agents used in the treatment of various tumors.
It is a taxane which interferes with microtubule depolymerization in tumor cells resulting in
an arrest of the cell cycle in mitosis followed by the induction of apoptosis. However, the high
lattice energy of paclitaxel results in very limited aqueous solubility (approximately 0.7–30
μg/ml) [1,2] contributing to only two commercialized dosage forms of injectable paclitaxel,
Taxol® and Abraxane®. Taxol® is composed of a 50:50 (v/v) mixture of Cremophor EL
(polyethoxylated castor oil) and dehydrated alcohol. Serious side effects, such as
hypersensitivity reactions, attributable to Cremophor EL have been reported [3]. In clinical
therapy, high doses of anti-histamines and gluococorticoids are co-administered to manage
these adverse effects, but this strategy has raised the possibility of additional pharmacokinetic
and pharmacodynamic issues with paclitaxel. To eliminate Cremophor EL from the paclitaxel
formulation, many alternative Cremophor EL-free formulations of paclitaxel have been
investigated. Abraxane® is one of those Cremophor EL-free paclitaxel formulations and was
registered with the FDA in 2005. Despite its improved clinical profile, Abraxane® is generally
not replacing Taxol in cancer chemotherapy, mostly due to its high cost. Therefore, alternative
and cost-effective parenteral formulations of paclitaxel are still needed.
Nanoparticles offer an alternative delivery system for cancer therapy that have the potential to
control the release rate of drug, improve the drug pharmacokinetics and biodistribution, and
reduce drug toxicity. Due to their small size, nanoparticles with entrapped drugs may penetrate
tumors due to the discontinuous and leaky nature of the microvasculature of tumors [4,5]. Also,
the characteristically poor lymphatic drainage of tumors may result in slower clearance of
nanoparticles that accumulate in tumors. This well known effect is referred to as the enhanced
permeability and retention (EPR) effect [6,7].
Lipid-based particulate delivery systems, including liposomes, micelles, nanocapsules, and
solid lipid nanoparticles have been developed especially to solubilize poorly water-soluble and
lipophilic drugs. These lipid-based systems have the advantage of being comprised of bio-
derived and/or biocompatible lipids that often result in lower toxicity. In general, the lipid-
based systems are made from the combination of lipophilic (oil), amphiphilic (surfactant) and
hydrophilic (water) excipients. Formulation approaches typically involve a highly interactive
process of experimentally investigating many variables including type and amount of
excipients, excipient combinations, and processes (i.e., high-pressure homogenization,
microfluidization, extrusion, microemulsion precursors, etc.). Appropriate type and amount of
excipients are critical variables, especially in the case of microemulsion precursors to prepare
lipid-based systems. Typically, phase diagrams with the blends of different excipients are first
developed using the water titration method. Then, combinations of excipients and the drug
substance are further optimized for their phase behavior and thermodynamic stability [8,9].
However, when several surfactants and/or oils are used, construction of phase diagrams
becomes quite tedious, expensive, and time consuming.
Experimental design is a statistical technique used to simultaneously analyze the influence of
multiple factors on the properties of the system being studied. The purpose of experimental
design is to plan and conduct experiments in order to extract the maximum amount of
information from the collected data in the smallest number of experimental runs. Factorial
design based on response surface method has been applied to design formulations [10,11].
However, an increase in the number of factors markedly increases the number of experiments
to be carried out. The so-called Taguchi approach proposes a special set of orthogonal arrays
to standardize fractional factorial designs [12]. By this approach, the size of factorial design
was reduced. As shown in Fig. 1, sequential simplex optimization is a step-wise strategy for
optimization that can adjust many factors simultaneously to rapidly achieve optimal response.
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The optimization is preceded by moving of a geometric figure (the “simplex”). The starting
simplex is composed of k + 1 vertex (experiments) wherein k is the number of variables. Then,
the experiments are performed one by one. The new simplex is obtained based on the results
from the previous simplex and the procedure is repeated until the simplex has rotated and
optimum is encircled. The variable-size simplex algorithm is the modified simplex algorithm
which allows the simplex to change its size during movement (Fig. 1). For detailed principles
and applications, the reader is referred to the specialized literature [13,14]. Thus, this process
of sequential simplex optimization allows for simultaneous formulation development and
optimization.
Our laboratory has already reported on the engineering of stable solid lipid-based nanoparticles
from oil-in-water (o/w) microemulsion precursors. Nanoparticles (E78 NPs) composed of
emulsifying wax (E. wax) as the lipid matrix and Brij 78 as the surfactant were reproducibly
prepared with particle sizes less than 150 nm. These E78 NPs were found to have excellent
hemocompatibility [15] and were shown to be metabolized in-vitro by horse liver alcohol
dehydrogenase (HLADH)/NAD+ [16]. Paclitaxel E78 NPs were shown to overcome Pgp-
mediated tumor resistance in-vitro in a human HCT-15 colon adenocarcinoma cell line [17]
and in-vivo in athymic nude mice bearing solid HCT-15 xenograft tumors [18]. However, a
shortcoming of the PX E78 NPs used in the above studies was that the entrapment efficiency
of paclitaxel in the NPs was only 50% which resulted in relatively rapid in-vitro release (over
80% in 8 h). These shortcomings were directly attributable to the relatively poor solubility of
PX in the melted E. Wax.
In light of the above, the objective of these studies was to develop Cremophor-free lipid-based
paclitaxel nanoparticle formulations that, 1) utilized acceptable oil phases having improved
solvation ability for PX, 2) had PX entrapment efficiency >80% with a minimum final
concentration of 150 μg/mL with over 5% drug loading, 3) resulted in slow(er) release profiles
of PX from NPs, and 4) had comparable in-vitro cytotoxicity to Taxol®. To achieve these
objectives, two medium-chain triglycerides, glyceryl tridodecanoate and Miglyol 812, were
selected as the oil phases to engineer nanoparticles from o/w microemulsion precursors.
Triglycerides are biocompatible/biodegradable excipients [19]. It has been reported that
paclitaxel has a high partition coefficient (Kp) in medium-chain triglycerides [20]. Glyceryl
tridodecanoate is solid at room temperature whereas Miglyol 812 is liquid at room temperature.
Thus, it was thought the use Glyceryl tridodecanoate and Miglyol 812 as oil phases may result
in the formation of solid lipid nanoparticles and nanocapsules, respectively. As discussed
above, simplex optimization or the combination of Taguchi array and sequential simplex
optimization was used to identify optimized systems based on initial response variables
(criteria) of particle size and polydispersity index. Identified leads were then fully characterized
for stability, entrapment efficiency, in-vitro release, and cytotoxicity in human MDA-MB-231
breast cancer cells.
2. Materials and methods
2.1. Materials and cell culture
Paclitaxel, glyceryl tridodecanoate, PBS, and Tween 80 were purchased from Sigma-Aldrich
(St. Louis, MO). Emulsifying wax and stearyl alcohol were purchased from Spectrum
Chemicals (Gardena, CA). Polyoxyl 20-stearyl ether was obtained from Uniqema
(Wilmington, DE). D-alpha-tocopheryl polyethylene glycol 1000 succinate was purchased
from Eastman Chemicals (Kingsport, TN). Miglyol 812 is a mixed caprylic (C8:0) and capric
(C10:0) fatty acid triglyceride and was obtained from Sasol (Witten, Germany). Dialyzers with
a molecular weight cutoff (MWCO) of 8000 were obtained from Sigma-Aldrich (St. Louis,
MO). Microcon Y-100 with MWCO 100 kDa was purchased from Millipore (Bedford, MA).
Ethanol USP grade was purchased from Pharmco-AAPER (Brookfield, CT). Taxol® was
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obtained from Mayne Pharma Inc. (Paramus, NJ). The human breast cancer cell line, MDA-
MB-231, was obtained from American Type Culture Collection (ATCC) and was maintained
in DMEM supplemented with 10% fetal bovine serum (FBS). Cells were cultured at 37°C in
a humidified incubator with 5% CO2 and maintained in exponential growth phase by periodic
subcultivation.
2.2. Preparation of nanoparticles from microemulsion precursors
Nanoparticles were prepared from warm o/w microemulsion precursors as previously
described with some modification [21]. Defined amounts of oil phases and surfactants were
weighed into glass vials and heated to 65°C. One (1) ml of filtered and deionized (D.I.) water
pre-heated at 65°C was added into the mixture of melted oils and surfactants. The mixture were
stirred for 20 min at 65°C and then cooled to room temperature. To prepare PX NPs, 150 μg
of PX dissolved in ethanol was added directly to the melted oil and surfactant and ethanol was
removed by N2 stream prior to initiating the process described above. Particle size and size
distribution of NPs were measured using a N5 Submicron Particle Size Analyzer (Beckman).
Ten microliters of nanoparticles were diluted with 1 ml of D.I. water to reach within density
range required by the instrument, and particle size analysis was performed at 90° light scattering
at 25°C.
2.3. Development of prototype nanoparticles by sequential simplex optimization
2.3.1. BTM Nanoparticles comprised of Miglyol 812, Brij 78 and TPGS—Miglyol
812 and stearyl alcohol were chosen as oil phases, and Brij 78 and TPGS were selected as the
surfactants. Taguchi array L-9 (34) was first used to help set up the starting simplex for
sequential simplex optimization. Particle size and polydispersity index (P.I.) were used to
evaluate the results. Three levels for each excipient and Taguchi array are presented in Table
1A. As directed by the results from Taguchi array, the starting simplex was constructed based
on the results of trial 3, 5, and 9 with a slight change for each component in each trial (Table
1B). Sequential simplex optimization then was performed as previously described following
the variable-size simplex rules [14]. Desirability functions previously developed for the
simultaneous optimization of different response variables (criteria) [22] were used to transform
response variables (particle size and P.I.) into a measure d (dsize or dP.I.) that could be
adequately compared and combined with other. Then, the measure of the individual response
variable was combined into an aggregated value (D value) by using a weighted geometric
average. Definitions of d and D value are presented in the equation (1) and equation (2),
respectively:
Equation (1)
In Equation (1), i indicates particle size or P.I. The limits were from a = 70 nm to b = 250 nm
for particle size, and from a = 0.05 to b = 1.2 for P.I. As the optimization in Table 1B was
complex, a larger range of P.I. was chosen in order to avoid too many “worst” trials in the
simplex, which could stop the simplex. In addition, the larger range of P.I. also helped to seize
all possible compositions in the optimization process. For these optimization experiments,
particle size and P.I. were given equal importance; thus, the constant s = 1. The overall
contribution of all responses is presented as a single aggregated D value as calculated by
Equation (2):
Equation (2)
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A comparison of each trial in the simplex optimization was based on this aggregated D value
which contained information from both particle size and P.I.
After the sequential simplex optimization, Miglyol 812, Brij 78 and TPGS were chosen to form
BTM NPs. Four different compositions based on the results from sequential simplex
optimization were tested (Table 1C) were prepared to further optimize BTM NPs.
2.3.2. G78 nanoparticles comprised of glyceryl tridodecanoate and Brij 78—G78
nanoparticles were optimized using MultiSimplex software (CambridgeSoft Corporation,
Cambridge, MA). The variable-size simplex rules were also used in this optimization, and
response variables included particle size, P.I. and the peak numbers in nanoparticle distribution.
The starting simplex was based on our previously optimized E78 NP composition (2 mg E.
wax and 4 mg Brij 78 in 1 ml NP suspension). Thus, the limits for particle size and P.I. were
naturally smaller than those for the sequential simplex optimization in Section 2.3.1. The limits
were from a = 50 nm to b = 200 nm for particle size, and from a = 0.01 to b = 0.4 for P.I., and
from a = 1 to b = 2 for peak numbers. Two milliliter NP formulations were prepared for each
composition.
2.4. Lyophilization of PX NPs
To determine the effect of lyophilization on the NPs, blank and PX NPs in the presence or
absence of 5% lactose were lyophilized using a VirTis® lyophilizer (SP Industries, Gardiner,
NY). Two milliliter of each sample was rapidly frozen at −40°C and then lyophilized using a
program of 7.5 h at −10°C for primary drying and 7.5 h at 25°C for secondary drying at 100
mTorr. The resultant lyophilized products were reconstituted in 2 ml of D.I. water using a plate
shaker for 5 min. The particle sizes of reconstituted lyophilized NPs from six different batches
were measured as described above.
2.5. Characterization of paclitaxel G78 and BTM nanoparticles
2.5.1. Particle size and zeta potential measurement—Nanoparticles were analyzed
for particle size and size distribution as described above. Ten microliter of blank NPs and PX
NPs were diluted with 1 ml of D.I. water and added 10 μl of PBS buffer (pH 7.4) for
measurement of Zeta potentials using Zetasizer Nano ZEN2600 (Malvern Instruments, Worcs,
U.K).
2.5.2. Determination of drug loading and entrapment efficiency—The concentration
of PX was quantified by HPLC using a Thermo Finnigan Surveyer HPLC System and an Inertsil
ODS-3 column (4.6 × 150 mm) (GL Sciences Inc.) preceded by an Agilent guard column
(Zorbax SB-C18, 4.6 × 12.5 mm). The mobile phase was water-acetonitrile (40:60, v/v) at a
flow rate of 1.0 ml/min with PX detection at 227 nm. For the paclitaxel standard curve,
paclitaxel was dissolved in methanol. To quantify PX in NPs, 1 part of PX NPs in water were
dissolved in 8 parts of methanol. PX BTM NPs containing 30% of 7-epi PX was dissolved in
methanol and then serially diluted in methanol to prepare the standard curve of 7-epi PX. Drug
loading and entrapment efficiencies were determined by separating free PX from PX-loaded
NPs using a Microcon Y-100, and then measuring PX in NP-containing supernatants as
described above. To ensure mass balance, the filtrates were also assayed for PX. PX loading
and PX entrapment efficiency were calculated as follows:
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2.5.3. Particle size stability of NPs in 4°C and 37°C—The physical stability of G78
and BTM nanoparticle suspensions was assessed over storage at 4°C for five months. Prior to
particle size measurement, NP suspensions were allowed to equilibrate to room temperature.
The stability of all NP suspensions was also assessed at 37°C in 10 mM PBS, pH 7.4 by adding
100 μL NP suspensions to 13 mL PBS buffer with a water-bath shaker mixing at 150 rpm. At
each time interval, 1 ml aliquots were removed and allowed to equilibrate to room temperature
prior to particle size measurement.
2.5.4. DSC analysis for G78 NPs—Differential scanning calorimetry (DSC) analysis was
performed to determine the physical state of the core (glyceryl tridodecanoate) lipid. Blank
G78 or PX G78 nanoparticle suspensions were concentrated about 20-fold using Microcon
Y-100 at 4°C. The concentrated NPs were; 1) analyzed by DSC immediately, or, 2) transferred
to an aluminum pan and that was placed in a desiccator for two days at room temperature prior
to DSC analysis. As controls, bulk glyceryl tridodecanoate (5 mg), Brij 78 (5 mg) and the bulk
mixture of glyceryl tridodecanoate (3.4 mg) and Brij 78 (8 mg) were placed in aluminum pans
for DSC analysis (PerkinElmer, Norwalk, CT). Heating curves were recorded using a scan rate
of 1°C/min from 15°C to 66°C.
2.5.5. In-vitro release studies—PX release studies (n = 4) were completed at 37°C by the
dialysis method using PBS with 0.1% Tween 80 as release medium. Before release studies,
the solubility of PX in release medium was measured. Briefly, extra amounts of paclitaxel were
added into 2 ml of release medium until saturation was attained. After centrifuge, the
concentration of PX in the supernatant was determined by HPLC as described above. For
release studies, one milliliter (1 ml) of PX G78 NPs were purified with a Microcon Y-100 and
re-suspended into 1 ml D.I. water. The concentration of PX in re-suspended PX G78 NPs was
measured by HPLC as described above. Eight hundred microliters of purified PX G78 NPs,
PX BTM NPs and reconstituted lyo BTM NPs were placed into a regenerated cellulose dialysis
membrane (MWCO 8000 Da) submerged in 40 ml PBS with 0.1% Tween 80, respectively,
and then shaken in a water bath at a speed of 150 rpm at 37°C. Free PX was also used as a
control. At predetermined times, 200 μL aliquots were taken from outside of the dialysis
membrane, and replaced with 200 μL fresh media. PX was measured by HPLC as described
above. Mass balance was confirmed by measuring PX concentration inside the dialysis
membranes after 72 h. In addition, the particle sizes of PX NPs inside the dialysis membranes
were measured when release studies were terminated (at 72 h).
2.6. In-vitro cytotoxicity studies
The cytotoxicity of PX NPs was tested in human MDA-MB-231 breast cancer cells using the
sulforhodamine B (SRB) assay [23]. Cells were seeded into 96-well plates at 1.5 × 104 cells/
well and cells were allowed to attach overnight. Cells were incubated for 48 h with drug
equivalent concentrations ranging from 10,000 nM to 0.01 nM for Taxol®, PX-loaded NPs and
blank NPs. The SRB assay was performed and IC50 values were determined. Briefly, the cell
lines were fixed with cold 10% trichloroacetic acid and stained using 0.4% SRB dissolved in
1% acetic acid. The bound dye was solubilized with 10 mM tris base, and the absorbance was
measured at 490 nm using a microplate reader. IC50 values were calculated based on the
percentage of treatment over control. All groups included three independent experiments (N
= 3) with triplicates (n = 3) for each experiment.
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Statistical comparisons were made with ANOVA followed by pair-wise comparisons using
Student’s t test using GraphPad Prism software. Results were considered significant at 95%
confidence interval (p < 0.05).
3. Results
3.1. Development of BTM nanoparticles by Taguchi array and sequential simplex
optimization
It has previously been reported that a combination of liquid and solid lipid oils enhance drug
loading and stability in nanoparticles as compared to a only a solid lipid core [24,25]. In the
initial development of NPs, a combination oil phase of Miglyol 812 (liquid oil) and stearyl
alcohol (solid oil) were selected, in addition to two potential surfactants, Brij 78 and TPGS.
Thus, based on these four variables (excipients), Taguchi array was carried out to determine
the extent of compositions to which the starting simplex could be formed efficiently. Taguchi’s
orthogonal array for 3 levels 4 variables (L-9 34) is shown in Table 1A. As depicted, trial 3, 5
and 9 gave the most promising results. Thus, the compositions of these three trials (3, 5, and
9) were used to construct the starting simplex in the sequential simplex optimization (Table
1B). As described in the methods section, there were two basic criteria for current nanoparticle
formulation: particle size (<200 nm) and P.I. (< 0.35). D value from desirability functions
including particle size and P.I. as response variables was used to evaluate the result of each
experiment. Interestingly, the simplex (trial 6 in Table 1B) identified an initial NP formulation
that did not contain stearyl alcohol (the solid oil component), but was comprised of Miglyol
812, Brij 78 and TPGS. Thus, as directed by simplex, subsequent experiments focused on these
three excipients. Four different compositions were used to prepare nanoparticles as shown in
Table 1C. Among them, trial 2 resulted in optimized NPs having a mean particle size of 149
nm and P.I. of 0.328. Interestingly, due to the relatively low concentration of the resulting NPs,
150 μg/ml of paclitaxel could not be entrapped into these NPs. However, when each component
was increased by a factor of 2.5, the more concentrated NP formulation was able to
accommodate the desired concentration of PX without changes in particle size and P.I.. This
final BTM NP formulation consisted of 2.5 mg of Miglyol 812, 1.5 mg of TPGS and 3.5 mg
of Brij 78 in 1 ml water with 150 μg/ml of paclitaxel.
3.2. Development of G78 nanoparticles by sequential simplex optimization
A solid lipid, glyceryl tridodecanoate was selected as an alternative to lipid-based NPs. glyceryl
tridodecanoate was selected as a possibly direct replacement of E. Wax in the previously
described E78 NPs due to the enhanced solubility of PX in glyceryl tridodecanoate. Thus, in
this simplex optimization, there were two variables, glyceryl tridodecanoate (oil) and Brij 78
(surfactant). The initial simplex was directed by the MultiSimplex software based on the
reference values of 2 mg for glyceryl tridodecanoate and 4 mg for Brij 78 in 1 ml water. Simplex
optimization then proceeded as shown in Table 2. After 8 trials, the optimized composition
reached nearly constant values in trials 9–11 of 1.6–1.9 mg for glyceryl tridodecanoate and 4–
4.2 mg for Brij 78 in 1 ml NP suspension. Finally, trial 11 was identified as the most optimized
composition since the composition gave the smallest particle size and the formulation could
easily accommodate 150 μg/ml of paclitaxel.
3.3. Lyophilization of BTM and G78 nanoparticles
The lyophilization of BTM NPs and PX BTM NPs in water alone resulted in the formation of
dry white cakes that were rapidly rehydrated with water within <15 seconds to produce clear
NP suspensions wherein the NPs showed complete retention of original physicochemical
properties and in-vitro release properties (Fig. 2 and Fig. 6). In contrast, lyophilized G78 NPs
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or PX G78 NPs in the presence or absence of 5% lactose as a cryoprotectant could not be
rehydrated in water and produced aggregates/agglomerates after rehydration.
3.4. Particle size and zeta potential
All tested nanoparticles had mean particle size diameters less than 200 nm with zeta potentials
of about −6 mV regardless of PX entrapment. The entrapment of paclitaxel had no influence
on the mean particle size of G78 and BTM nanoparticles (Table 3). Interestingly, rehydrated
lyophilized NPs had smaller particle sizes for both blank BTM NPs and PX BTM NPs (Fig.
2).
3.5. Drug loading and entrapment efficiencies of paclitaxel in nanoparticles
HPLC analysis showed that the 7-epi isomer of PX was present at about 30% when PX was
formulated in NPs in water. Further analysis showed that the epimerization occurred during
preparation of the PX NPs [26]. However, epimerization at C7 is reversible and can be
prevented by forming PX NPs at slightly acidic pH [27]. 7-epi isomer of PX did not form when
PX BTM NPs were prepared in 10% lactose (pH = 5) or 50 mM sodium acetate buffer (pH =
6). The slope of the standard curve for 7-epi PX was not statistically different from that for PX
(data not shown). Thus, the standard curve for PX was used to determine the total PX
concentration (PX plus 7-epi PX).
The entrapment efficiencies for PX G78 NPs and PX BTM NPs were 85% and 97.5% as shown
in Table 3. The mass balance of PX was 85.4 ± 3.3 % and 102.7 ± 2.0 % (mean ± SD, n = 3)
for PX G78 NPs and PX BTM NPs, respectively. The results showed that paclitaxel was
incorporated into nanoparticles at weight ratio of over 6% of the selected lipid core. Finally,
rehydrated lyophilized PX BTM NPs showed 93.1% of entrapment efficiency, which was not
statistically different to that of non-lyophilized PX BTM NPs (p > 0.05).
3.6. Physical stability of nanoparticles
The physical stability of paclitaxel nanoparticles was evaluated by monitoring changes of
particle sizes at 4°C upon long-term storage as well as short term stability at 37°C in PBS to
simulate physiological conditions. The particle sizes of G78 and BTM nanoparticles with or
without paclitaxel did not significantly change at 4°C for five months (Fig. 3). To test stability
of nanoparticles in physiological condition, G78 NPs, BTM NPs and reconstituted lyophilized
BTM NPs were incubated in PBS at 37°C for 102 h. Particle sizes of PX-loaded and blank
nanoparticles slightly increased after 72 h incubation. The data for PX-loaded NPs are shown
in Figure 4 whereas the data for blank NPs are not shown.
3.7. Physical state of the core lipid in G78 nanoparticles
It has been reported that glyceryl tridodecanoate (also called ‘trilaurin’) existed as supercooled
melts rather than in a solid state in nanoparticles [28,29]. Thus, in the present studies, DSC
analysis was used to determine the physical state of glyceryl tridodecanoate in G78
nanoparticles. Bulk glyceryl tridodecanoate showed the melting peak at 46°C while Brij 78
had two melting peaks at 35°C and 40°C. The concentrated blank and PX G78 NPs clearly
showed an endothermal peak at 43°C (Fig. 5B). After drying of the NPs, two other peaks at
35°C and 40°C appeared for blank or PX G78 NPs (Fig. 5A). The endothermal peaks of Brij
78 intensified after drying suggesting that more Brij 78 existed in the solid state. The melting
peak of glyceryl tridodecanoate in nanoparticles shifted to lower temperature and broader
compared to that of bulk material. However, the endothermic peak at 43°C for glyceryl
tridodecanoate indicated that glyceryl tridodecanoate retained a solid state in G78
nanoparticles.
Dong et al. Page 8













3.8. In-vitro release of paclitaxel from nanoparticles
Paclitaxel has been reported to have aqueous solubility of 0.7–30 μg/ml. Therefore, to maintain
sink conditions, PBS with 0.1% Tween 80 was used as the release medium for the in-vitro
release studies of paclitaxel. The solubility of paclitaxel in release medium at room temperature
was 10.8 ± 0.3 μg/ml (mean ± SD, n = 3) as measured by HPLC. Thus, for the release studies,
800μl of PX NPs containing 150 μg/ml of paclitaxel were placed into 40 ml of release medium.
There was no 7-epi PX observed during the release study of free paclitaxel. The cumulative
release of paclitaxel from PX NPs was calculated based on the total PX (PX plus 7-epi PX)
released and is shown in Fig. 6. Free PX was released completely within 4 h. For all tested PX
NPs, although the initial release rates were greater between 0 and 8 h, no initial burst of PX
was observed. After 8 h, the release rates were much lower. The results showed that the mean
cumulative release of PX after 72 h was 40%, 50% and 53% from PX G78 NPs, PX BTM NPs
and reconstituted lyophilized PX BTM NPs, respectively. Mass balance analysis for PX G78
NPs, PX BTM NPs and lyophilized PX NPs showed that 79.2 ± 8.6 %, 98.3 ± 24.2 %, and 73.4
± 16.6 % (mean ± SD, n = 4) of the PX was recovered, respectively. There were no other PX
degradation peaks, except for 7-epi PX, observed by HPLC during the course of the studies.
Moreover, lyophilized PX BTM NPs showed the same release profile as compared to PX BTM
NPs (p > 0.05 at each time point). Also, the particle sizes of all tested nanoparticles did not
change significantly after 72 h.
3.9. In-vitro cytotoxicity studies
The cytotoxicity of PX NPs was tested in human breast cancer MDA-MB-231 cells using the
SRB assay (Table 4). PX NPs showed a clear dose-dependent cytotoxicity in MDA-MB-231
cells. There was no statistical significance in the IC50 values of PX BTM NPs and lyophilized
PX BTM NPs compared to commercial Taxol®. However, the IC50 of PX G78 NPs had
comparable but statistically different IC50 values compared to Taxol®. Blank NPs showed
some cytotoxicity but only the paclitaxel equivalent dose of 617.3 nM and 354.6 nM of PX
which corresponds to a total NP concentration of 26.4 μg/ml and 15.1 μg/ml for blank G78
NPs and BTM NPs, respectively.
4. Discussion
Paclitaxel is an important agent in the treatment of metastatic breast cancer. However, the
optimal clinical use of paclitaxel is limited due to its poor aqueous solubility. Commercial
paclitaxel formulation, Taxol®, is generally associated with hypersensitivity reactions which
results from the excipient Cremophor EL in Taxol®. To overcome the problems, numerous
lipid-based and Cremophor EL-free paclitaxel formulations have been investigated, such as
liposomes [30], solid lipid nanoparticles [31,32], micelles [33,34], emulsions [35,36].
In the present study, two median chain triglycerides, glyceryl tridodecanoate and Miglyol 812,
were used to investigate new lipid-based nanoparticles for paclitaxel. Relative to other
candidate oil phases, these two oils have high solvation ability for PX. Glyceryl tridodecanoate
has a relatively low melting point of 46°C, which theoretically facilitates the preparation of
lower crystalline cores which may accommodate a greater concentration of drug [25]. Miglyol
812, being a liquid, forms a reservoir-type drug delivery systems in which poorly water-soluble
drugs remain dissolved inside the liquid oil core and consequently a high payload and reduced
release profile may be achieved [37,38]. As expected, the final optimized nanoparticles, G78
NPs and BTM NPs, successfully entrapped paclitaxel with high loading and entrapment
efficiency (Table 3). However, the selection of these two alternative oil phases required the
development of optimized NP formulations. To facilitate, we used a methodology that
combined Taguchi array and sequential simplex optimization. The simplex is made of k + 1
vertex. The response of the experiment in each vertex is ranked and the “worst” response is
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replaced by the new set of variables for the next experiment. To efficiently move the simplex,
there should be limited “worst” responses in the staring simplex. As new excipients are
encountered and no known compositions could be referred (Table 1), Taguchi array was first
performed to explore and provide the framework of the starting simplex. The final optimization
was then completed using sequential simplex optimization. Trial 6 in Table 1B identified a
new nanoparticle formulation composed of the liquid oil Miglyol 812. After further
optimization, new BTM nanoparticles were developed. For new compositions but which can
be referred as E78 NPs (Table 2), the sequential simplex optimization was directly used for
investigation of G78 NPs. The results for both PX NPs indicate that this new methodology
combining Taguchi array and sequential simplex optimization could efficiently and effectively
be used to identify optimized nanoparticles. Finally, a total of 19 trials and 11 trials were used
to obtain optimized BTM NPs and G79 NPs, respectively. In contrast, even for 4 factors and
3 levels design, e.g. optimization in Table 1A and 1B, complete factorial design would require
34 = 81 experiments. To our best knowledge, this is the first report to use the combination of
Taguchi array and sequential simplex optimization for the development of nanoparticles.
Choosing appropriate lipids could help increase the entrapment efficiency of drug and slow
the release rate of the drug from the nanoparticles. As Compared with PX E78 NPs previously
developed in our lab, the optimal PX BTM and G78 nanoparticles were very reproducible with
high drug loading and showed much slower release of PX achieving about 50% and 40% after
72 h, respectively (Fig. 6). The slow and sustained release of paclitaxel without burst release
from PX BTM and PX G78 nanoparticles indicated that paclitaxel was likely not present at or
near the surface of nanoparticles but instead within the core of the NPs as ideally predicted by
the enhanced solvation ability of Miglyol 812 and glyceryl tridodecanoate for PX. Moreover,
entrapment of paclitaxel into nanoparticles did not change the sizes of nanoparticles. All PX
NPs had particle sizes less than 200 nm, even after 102 h of incubation in PBS at 37°C. These
data indicate potential stability of PX NPs in-vivo after intravenous injection (Fig. 4).
Cytotoxicity studies showed that both PX G78 and BTM nanoparticles had the same or
comparable anticancer activity compared to commercial Taxol® in human MDA-MB-231
breast cancer cells. Therefore, both of these identified PX NP formulation may be good
candidates for ligand-mediated tumor-targeted delivery of PX.
Several studies have reported that glyceryl tridodecanoate is retained in lipid-based NPs in a
super-cooled liquid state. If true, this semi-stable state of glyceryl tridodecanoate will likely
affect the stability of nanoparticles due to the predicted phase transition of the super-cooled
core to the crystalline phase. However, the present studies showed using DSC analysis that
glyceryl tridodecanoate remained as a solid state in G78 NPs (Fig. 5), suggesting that the
phenomenon of super-cooled glyceryl tridodecanoate in nanoparticles may be dependent on
the process and compositions (i.e., surfactant) used to prepare the nanoparticles. Blank and PX
G78 nanoparticles stored as liquid suspensions at 4°C remained stable for several months and
exhibit no change in particle size. There was some concern that G78 nanoparticles, made with
the lower melting GT, may be adversely affected by body temperature. However, either blank
or PX G78 nanoparticles showed no change in particle sizes after 102 h of incubation in PBS
at 37°C.
It is thought that BTM NPs may be a novel liquid reservoir, or nanocapsule-type formulation.
The liquid reservoir containing paclitaxel dissolved in Miglyol 812 is stabilized with the
polymeric surfactants Brij 78 and TPGS. Higher drug loading of PX BTM nanoparticles
indicate the advantage of this nanocapsule-type formulation as compared to the solid-core type
G78 NP system. The BTM NPs were spontaneously formed after cooling from the warm o/w
microemulsion precursors. It is thought that the BTM NPs are nanocapsules and not
nanoemulsions since nanoemulsions are non-equilibrium and thermodynamically unstable
systems that cannot, by definition, form spontaneously without agitation or significant
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mechanical/shear mixing [39]. Another very interesting discovery was serendipitously made
during the course of the present studies. In one attempt to concentrate NP formulations to
analyze for entrapped PX, NPs were lyophilized in water. The BTM NP formulations produced
uniform white cakes that could be rapidly rehydrated with complete retention of original
physicochemical properties, in-vitro release properties, and cytotoxicity profile. Our
experience, as well as others, is that it is often difficult to freeze-dry colloidal suspensions in
the presence of cryoprotectants. To our knowledge, there are few or no reports on the successful
lyophilization of colloidal suspensions without the use of a cryoprotectant which protects the
nanoparticles from the stresses of the freezing and thawing process. Moreover, the
lyophilization of nanoemulsions or nanocapsules is thought to be even more challenging due
to the existence of the very thin and fragile lipid envelope that may not withstand the mechanical
stress of freezing [40,41]. Even in the presence of cryoprotectants, increase of particle size are
likely to occur [42]. In the present studies, the optimal BTM nanoparticles were successfully
lyophilized without cryoprotectants. The non-collapsed uniform cakes of PX BTM NPs in
water alone was rehydrated and spontaneously produced particle sizes that were, in fact,
slightly smaller than the original particle sizes. In addition, there was complete retention of the
in-vitro release properties and cytotoxicity profile.
In conclusion, the combination of Taguchi array and sequential simplex optimization
efficiently guided the development and optimization of lipid-based nanoparticulate
formulation for paclitaxel. Injectable paclitaxel nanoparticles, PX G78 NPs and PX BTM NPs,
were successfully prepared via a warm o/w microemulsion precursor engineering method. Both
paclitaxel nanoparticle suspensions were physically stable at 4°C over five months, and PX
BTM could be lyophilized without cryoprotectants. PX G78 and BTM nanoparticles showed
comparable or same anticancer activity compared to Taxol® in MDA-MB-231 breast cancer
cells. Therefore, these paclitaxel-loaded nanoparticles may be candidates for ligand-mediated
tumor-targeted delivery of paclitaxel after intravenous injection.
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The principles of sequential simplex optimization for two variables using variable-size simplex
rules on the response surface [14]. The starting simplex consists of vertexes 1, 2 and 3 where
1 gives the worst response. The second simplex consists of vertexes 2, 3, and 4 after a reflection
and expansion. Finally, the movement of the simplex results in the simplex 12, 14, and 15
which indicates the optimum.
Dong et al. Page 14














Particle size of BTM nanoparticles before and after lyophilization (and rehydration). Six
different batches were tested for both blank BTM nanoparticles and PX-loaded BTM
nanoparticles. For all tested NP formulations, P.I. values ranged from 0.03 to 0.35 indicating
uniform, mono-dispersed NPs. Data are presented as the mean particle size of three separate
measurement of each batch.
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Long-term stability of paclitaxel nanoparticles stored at 4°C. Three different batches of PX-
loaded BTM and G78 nanoparticles were monitored for particle sizes over five months. For
all tested samples, P.I. <0.35. Data are presented as the mean particle size of three separate
measurement of each batch.
Dong et al. Page 16














Stability of paclitaxel nanoparticles in PBS at 37°C. PX BTM nanoparticles, reconstituted
lyophilized PX BTM nanoparticles and PX G78 nanoparticles were monitored for particle sizes
for 102 h. For all tested samples, P.I. <0.35. Data are presented as the mean particle size of
three separate measurement of each batch.
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DSC for G78 nanoparticles. (A) DSC analysis of nanoparticles was performed immediately
after concentrating nanoparticles (“dry”). (B) The concentrated nanoparticles were dried by
desiccations for two days prior to DSC analysis (“wet”). GT means glyceryl tridodecanoate.
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Release of PX from PX nanoparticles at 37°C. Paclitaxel release was measured using the
dialysis method in PBS (pH 7.4) with 0.1% Tween 80 as described in the Method section. Data
are presented as the mean ± SD (n = 4).
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